Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V. - ppt video online download
ARNI: sacubitril/valsartan. Mechanism of action, dosage, indications, side effects - YouTube
Preventing Heart Failure Readmission and Progression - ppt download
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition | Circulation
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure | Revista Portuguesa de Cardiologia (English edition)
Figure 2 from Treatment with LCZ 696 is likely to change first-line treatment of heart failure LCZ 696 – a promising new compound in heart failure treatment | Semantic Scholar
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure - ScienceDirect
New Drugs: Sacubitril/Valsartan
From ARB to ARNI in Cardiovascular Control. - Abstract - Europe PMC
Mechanism of action of LCZ696. LCZ696 is a dual-acting neprilysin... | Download Scientific Diagram
Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development | Future Cardiology
Figure 1 from Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. | Semantic Scholar
Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug? | Circulation
Angiotensin receptor-neprilysin inhibitors: clinical potential in hear | VHRM
Arni
Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction | Future Cardiology
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
Entresto Mechanism of Action [Video] in 2021 | Vasoconstriction, Heart failure treatment, Vasodilation
Arni
Schematic representation to show the mode of action of an ARNI. NPs are... | Download Scientific Diagram
Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives - International Journal of Cardiology